Cybin CEO Doug Drysdale On What Distinguishes CYB003 from Other Aspiring Novel Depression Treatments
Description
In our latest WTR Small-Cap Spotlight x Healthcare Crossover, Cybin CEO Doug Drysdale joins Water Tower Research’s Tim Gerdeman and Senior Analyst Robert Sassoon to discuss the company's non-traditional financing strategy as it continues to advance its development pipeline. Drysdale also probes into data that highlight advantages that distinguish Cybin's lead program CYB003 from other aspiring late-stage novel therapies in the depression treatment landscape
Cybin (NYSE: CYBN) is a late-stage clinical development company focused on developing novel psychedelic-based neuropsychiatric compounds. Its two lead candidates, targeting two of the most pervasive mental health disorders, are psilocin-based CYB003 for Major Depressive Disorder (MDD), currently being dosed in a Phase 3 program, and DMT-based CYB004 for General Anxiety Disorder (GAD) which is wrapping up a Phase 2 study.
United States
